AMCP Substance Use Disorder Advisory Group: A Focus on Prescription Drug Use
Despite efforts to decrease the use of opioids, challenges remain. AMCP created multiple advisory groups beginning in 2015, recognizing the widespread and devastating nature of the opioid crisis. Over time, these groups addressed access to medications for the treatment of substance use disorders and developed a viewpoint document on the importance of co-prescribing naloxone. The purpose of this group is to continue the work of the previous groups and focus on collecting and disseminating guidelines for managed care pharmacists regarding integrated care models and benefit designs that effectively address substance use disorder.
- Myths & Misconceptions That Impact Appropriate Treatment for Opioid Use Disorder (OUD)
- Co-Prescribing Naloxone Manuscript
- Impact of COVID-19 on Treatment of Substance Use Disorders Webinar
(Members Only) This webinar will describe the impact of COVID-19, associated mitigation measures strategies, regulatory changes, and innovations for patients with SUD.
- The Role of Managed Care in Addressing Health Disparities in Substances Use Disorder Treatment Webinar
This webinar will describe how health disparities impact patients with SUD and their access to treatment programs.
The work of the SUD advisory group was supported by Pear Therapeutics.